A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | EGFR |
Clinical data | |
Trade names | Portrazza |
AHFS/Drugs.com | Multum Consumer Information |
License data |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | ~14 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6436H9958N1702O2020S42 |
Molar mass | 144844.87 g·mol−1 |
![]() ![]() |
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]
References
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28.
- ^ "Necitumumab". Approved Drugs. U.S. Food and Drug Administration. Archived from the original on 2017-01-11. Retrieved 2019-12-16.
- ^ a b "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Retrieved 2019-09-28.
- ^ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.
>Text je dostupný pod licencí Creative Commons Uveďte autora – Zachovejte licenci, případně za dalších podmínek. Podrobnosti naleznete na stránce Podmínky užití.
Text je dostupný za podmienok Creative
Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších
podmienok.
Podrobnejšie informácie nájdete na stránke Podmienky
použitia.